🩸🎯 Today's question!

Swipe to see the answer and its explanation.

#CMML #Hematology #HemeOnc #MyeloidNeoplasms #BoneMarrow #HEMEHUB #Monocytes #TET2 #ASXL1 #ChronicMyelomonocyticLeukemia #Venetoclax #Azacitidine #AML #Leukemia #MedicalEducation #MedEd #HemeEd

Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia Acquired von Willebrand syndrome represents a rare but significant complication of chronic lymphocytic leukemia. This patient achieved remission after treatment with venetoclax plus obinutuzumab.

#MedCase - Acquired von Willebrand syndrome represents a rare but significant complication of chronic lymphocytic #leukemia.

This patient achieved remission after treatment with #venetoclax plus #obinutuzumab.

👉 buff.ly/2QrQ0LE

#OncSky

ZW27941, a potent VHL-based #PROTAC, degrades METTL3/METTL14 to suppress #AML by downregulating c-Myc/BCL2 and disrupting key pathways, while synergizing with #cytarabine & #venetoclax for therapy. @ufresearch.bsky.social @ufhealthcancer.bsky.social

Read: doi.org/10.1016/j.ge...

AbbVie’s Venetoclax Receives FDA Approval for CLL Combination Therapy AbbVie announces FDA approval for Venetoclax in combination with Acalabrutinib for untreated chronic lymphocytic leukemia, enhancing treatment options.

AbbVie’s Venetoclax Receives FDA Approval for CLL Combination Therapy #United_States #AbbVie #North_Chicago #CLL #venetoclax

Compared with #pomalidomide and #dexamethasone, #venetoclax and dexamethasone did not produce statistically different PFS in those with R/R t(11;14) multiple #myeloma #MMsm, an indication that the combo may not be a good option in this patient population: https://ow.ly/Z0Pf50YsTST
#HemeSky #MedSky

#mTORC1 inhibition activates the integrated stress response, upregulates pro-apoptotic BMF, and sensitizes resistant T-ALL to #Venetoclax; Everolimus–Venetoclax synergy reduces #leukemic burden in #PDXmodels. #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...

Tumori, ematologo Cuneo: "In Llc grandi vantaggi da acalabrutinib e venetoclax" (Adnkronos) - Su nuovi dati studio AMPLIFY in leucemia linfatica cornica, ‘combinazione orale a durata fissa si distingue per efficacia, maneggevolezza, tolleranza e sostenibilità’ “A tre anni dalla terapia, 9 pazienti su...

È ACCADUTO IERI: Tumori, ematologo Cuneo: "In Llc grandi vantaggi da acalabrutinib e venetoclax" ... LEGGI TUTTO #Tumori #Ematologia #Leucemia #Acalabrutinib #Venetoclax

Tumori, ematologo Cuneo: "In Llc grandi vantaggi da acalabrutinib e venetoclax" (Adnkronos) - Su nuovi dati studio AMPLIFY in leucemia linfatica cornica, ‘combinazione orale a durata fissa si distingue per efficacia, maneggevolezza, tolleranza e sostenibilità’ “A tre anni dalla terapia, 9 pazienti su...

Tumori, ematologo Cuneo: "In Llc grandi vantaggi da acalabrutinib e venetoclax" ... LEGGI TUTTO #tumori #ematologia #leucemialinfaticacronica #acalabrutinib #venetoclax

RedHill Biopharma Reports Promising Study Results on Opaganib's Role in Overcoming Venetoclax Resistance Recent findings from RedHill Biopharma indicate that opaganib, combined with venetoclax, could significantly reduce resistant CLL cell counts. This breakthrough may transform treatment strategies for patients facing venetoclax resistance.

RedHill Biopharma Reports Promising Study Results on Opaganib's Role in Overcoming Venetoclax Resistance #USA #Raleigh #RedHill_Biopharma #Opaganib #venetoclax

New Treatment Options for Untreated Chronic Lymphocytic Leukemia Using Imbruvica and Venetoclax The combination therapy of Imbruvica and Venetoclax presents a promising new treatment option for untreated chronic lymphocytic leukemia (CLL).

New Treatment Options for Untreated Chronic Lymphocytic Leukemia Using Imbruvica and Venetoclax #Japan #Tokyo #Chronic_Lymphocytic_Leukemia #venetoclax #Imbruvica

AbbVie Expands Treatment Options for Untreated CLL/SLL with Venetoclax Approval AbbVie has secured approval in Japan to expand the use of Venetoclax for treating untreated chronic lymphocytic leukemia and small lymphocytic lymphoma, offering new hope for patients.

AbbVie Expands Treatment Options for Untreated CLL/SLL with Venetoclax Approval #Japan #Tokyo #AbbVie #CLL #venetoclax

In a small study of #pediatric patients with high-risk #AML, the combination of FLAG-IDA plus #venetoclax appeared to be a highly effective frontline treatment regimen, with all patients achieving CR and most proceeding to #hematopoietic cell #transplant: https://ow.ly/a1Cm50Xu4Xv
#HemeSky #leukemia

The November issue is out now! Highlights include a cover story on medical #misinformation and articles on FLAG-IDA plus #venetoclax in #pediatric #AML, off-the-shelf NK cell therapy in R/R B-cell #lymphoma, and more. Check out the full lineup here: https://ow.ly/KJcM50XmEte
#HemeSky #MedSky

⚡️ #AB_Science : données de phase 1 de la combinaison d’#AB8939 et du #Venetoclax dans la #Leucémie myéloïde aiguë R/R ( #LMA 🩸)

Le taux de contrôle est de 100 % (3/3)
Le taux de réponse partielle est de 100 % (3/3)
Dont un patient en rémission complète.
www.boursica.com/informations...

This research letter provides a proof of concept that the pharmacological or genetic inhibition of mTOR sensitizes T-cell acute lymphoblastic leukemia cells to #Venetoclax via the sustained activation of #IntegratedStressResponse. #medsky

#OpenAccess: doi.org/10.1038/s413...

Individualized Therapy Associated With Greater Rates of Undetectable MRD, Extended PFS in CLL | ASH Clinical News | American Society of Hematology

In patients with treatment-naïve #CLL, MRD-guided therapy with #ibrutinib plus #venetoclax led to greater rates of undetectable MRD, extended PFS, and increased OS than ibrutinib alone or #chemoimmunotherapy, especially among patients with unmutated IGHV: ow.ly/oA2u50WWZZc #HemeSky #HemeOnc

Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia | JCO Oncology Practice PURPOSEVenetoclax and Bruton's tyrosine kinase inhibitors (BTKis) are key treatment options for patients with chronic lymphocytic leukemia (CLL) in the frontline setting. This study characterized post...

En el mundo real, la discontinuación temprana es más común en los pacientes que inician un BTKi que los que inician venetoclax con obinutuzumab, con una mayor tasa de hospitalización #venetoclax #BTKIs #CLL ascopubs.org/doi/full/10....

Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years - Alexis Talbot, Pierre-Ed... Background: Venetoclax is the first representative of a new class of targeted therapy, that inhibits selectively B-cell lymphoma-2 (BCL-2), an anti-apoptotic pr...

🎉Last paper from the team 📰
Retrospective study of all cases of adverse events (AEs) under #venetoclax recorded in the French pharmacovigilance database 🇫🇷 since its market approval.
➡️ 36% AEs were not listed in the SPC including autoimmune hemolytic anemias (2%) 🩸 or cardiac (7%) ❤️‍🩹

MRD-Guided Treatment Approach Leads to Deep Remissions in CLL | ASH Clinical News | American Society of Hematology

Recent research indicates that MRD-guided time-limited treatment with #zanubrutinib, #venetoclax, and #obinutuzumab resulted in deep remissions in patients with previously treated #ChronicLymphocyticLeukemia, with a best uMRD rate of 85%: ow.ly/e16h50WwZ66
#HemeSky

Real-World Venetoclax Combinations for MM Show Evidence of Efficacy in Patients Harboring t(11;14) | ASH Clinical News | American Society of Hematology

When used in combination with other medications, #venetoclax appears to be effective in patients with R/R #MultipleMyeloma #MMsm harboring t(11;14), with an ORR of 64%, but is less efficacious when certain other chromosomal abnormalities are also present: ow.ly/BcQU50Wo0Vw
#HemeSky #HemeOnc

Taiho Oncology Pursues Innovative AML Treatment with FDA's Acceptance of INQOVI® sNDA Taiho Oncology's application for INQOVI in combination with venetoclax has been accepted by the FDA, aiming to treat newly diagnosed AML patients who cannot undergo intense chemotherapy.

Taiho Oncology Pursues Innovative AML Treatment with FDA's Acceptance of INQOVI® sNDA #United_States #Princeton #Acute_Myeloid_Leukemia #venetoclax #INQOVI

Zanubrutinib Plus Venetoclax Shows Efficacy in Treatment-Naïve CLL | ASH Clinical News | American Society of Hematology

In the SEQUOIA study, combination #zanubrutinib and #venetoclax for treatment-naïve #CLL/SLL resulted in complete response in about half of patients in arm D of the study, with authors noting high response rates regardless of mutational status #ASCO2025: ow.ly/PCT450W9acZ
#HemeSky #HemeOnc #MedSky

AbbVie Announces Results from Phase 3 VERONA Trial for Treating High-Risk Myelodysplastic Syndromes AbbVie has released findings from its Phase 3 VERONA study, exploring venetoclax and azacitidine for higher-risk myelodysplastic syndromes, highlighting significant results.

AbbVie Announces Results from Phase 3 VERONA Trial for Treating High-Risk Myelodysplastic Syndromes #USA #AbbVie #North_Chicago #venetoclax #azacitidine

Can venetoclax-based therapy reshape frontline AML treatment?
Promising data suggest a potential shift in outcomes for newly diagnosed patients.
Read more via The ASCO Post ⬇️
🔗 ascopost.com/news/may-202...
#ASCO2025 #AML #Oncology #Leukemia #Venetoclax #CancerResearch

De novo AML spontaneously achieved PR after COVID-19... : Medicine admitted to our department with fever, cough dyspnea, and thrombocytopenia for 1 week. Diagnoses: The patient was diagnosed with AML associated with a TP53 mutation and complex chromosomal abnormal...

She spontaneously achieved PR after server #COVID, & CR after reduced dose of #azacytidine combined with #venetoclax.

journals.lww.com/md-journal/f...

Talha Badar: Venetoclax plus 3+7 for newly diagnosed acute myeloid leukemia - OncoDaily Talha Badar: Venetoclax plus 3+7 for newly diagnosed acute myeloid leukemia / Acute Myeloid Leukemia, Aditi Shastri, Amit Verma, AML, cancer, Dennis Cooper,

Venetoclax plus 3+7 for newly diagnosed acute myeloid leukemia - Talha Badar
@talhabadarmd.bsky.social

oncodaily.com/science/talh...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Venetoclax #AML #AcuteMyeloidLeukemia

AMPLIFY for 1L CLL now in @nejm.org

🔑 takeaways:

1️⃣ Fixed-duration #acalabrutinib + #venetoclax (±obinutuzumab) improved PFS (3-year): 76% (A+V), 83% (AVO) vs 66% (Chem)

2️⃣ AVO showed deeper responses but higher infection risk

3️⃣ New SoC for many

#OncSky #CanSky #HemeSky

Venetoclax: Todo lo que Necesitas Saber sobre este Medicamento Innovador ¿Qué es Venetoclax y cómo funciona en el tratamiento del cáncer? Venetoclax es un medicamento innovador utilizado en el tratamiento de ciertos tipos de cáncer, especialmente en la leucemia linfocítica crónica (LLC) y en... The post Venetoclax: Todo lo…

Venetoclax: Todo lo que Necesitas Saber sobre este Medicamento Innovador #Venetoclax #Cáncer #Leucemia

Dr. Matthew Cortese from Roswell Park Comprehensive Cancer Center giving a presentation on his research on "Multiomic Evaluation of Immunologic Changes in Chronic Lymphocytic Leukemia with Venetoclax Treatment” at the 2024 American Society of Hematology’s annual meeting.

Kudos to Dr. Matthew Cortese for his outstanding presentation this morning on “Multiomic Evaluation of Immunologic Changes in Chronic Lymphocytic Leukemia with Venetoclax Treatment.”

Your research is advancing our understanding of #CLL and the impact of #venetoclax.

#ASH24